Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	1: Budesonide-MMX® 6 mg	126
Overall Study	STARTED	2: Budesonide-MMX® 9 mg	127
Overall Study	STARTED	3: Placebo	129
Overall Study	STARTED	4: Asacol® 400 mg	127
Overall Study	COMPLETED	1: Budesonide-MMX® 6 mg	89
Overall Study	COMPLETED	2: Budesonide-MMX® 9 mg	89
Overall Study	COMPLETED	3: Placebo	76
Overall Study	COMPLETED	4: Asacol® 400 mg	95
Overall Study	NOT COMPLETED	1: Budesonide-MMX® 6 mg	37
Overall Study	NOT COMPLETED	2: Budesonide-MMX® 9 mg	38
Overall Study	NOT COMPLETED	3: Placebo	53
Overall Study	NOT COMPLETED	4: Asacol® 400 mg	32

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00679432/flow